Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Point in time of the first visible deviation from the trail in each scenario. by Chengmin Zhou (14554562)

Subjects:

Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

Subjects:

Mean (SDs) of take-over reaction times according to scene complexity and type of autonomous driving information display. by Chengmin Zhou (14554562)

Subjects:

NCOA4 protein expression is downregulated and GPX4 protein expression was significantly upregulated in CCA cells. by Wenlong Shen (9313937)

Subjects:

Mean (SD) of fixation duration, fixation counts, and SAGAT accuracy according to scene complexity and autonomous driving information display type. by Chengmin Zhou (14554562)

Subjects:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The mean and standard error of SAGAT accuracy for type A, type B, and type C autonomous driving information display types under various scenario complexities. by Chengmin Zhou (14554562)

Subjects:

The mean and standard error of fixation duration for type A, type B, and type C autonomous driving information display types under various scenario complexities. by Chengmin Zhou (14554562)

Subjects:

The mean and standard error of fixation counts for type A, type B, and type C autonomous driving information display types under various scenario complexities. by Chengmin Zhou (14554562)

Subjects:

The mean and standard error of take-over reaction time for type A, type B, and type C autonomous driving information display types under various scenario complexities. by Chengmin Zhou (14554562)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects: